B-intervention	0	11	Progressive
I-intervention	12	22	resistance
O	23	29	versus
B-control	30	40	relaxation
I-control	41	49	training
O	50	53	for
O	54	60	breast
O	61	67	cancer
O	68	76	patients
O	77	83	during
O	84	92	adjuvant
O	93	105	chemotherapy
O	105	106	:
O	107	113	design
O	114	117	and
O	118	127	rationale
O	128	130	of
O	131	132	a
O	133	143	randomized
O	144	154	controlled
O	155	160	trial
O	161	162	(
O	162	167	BEATE
O	168	173	study
O	173	174	)
O	174	175	.

O	176	182	Cancer
O	182	183	-
O	183	190	related
O	191	198	fatigue
O	199	201	is
O	202	203	a
O	204	210	common
O	211	217	severe
O	218	225	symptom
O	226	228	in
O	229	235	breast
O	236	242	cancer
O	243	251	patients
O	251	252	,
O	253	263	especially
O	264	270	during
O	271	283	chemotherapy
O	283	284	.

O	285	293	Exercise
O	294	301	appears
O	302	304	to
O	305	307	be
O	308	317	promising
O	318	320	in
O	321	331	prevention
O	332	334	or
O	335	344	treatment
O	345	347	of
O	348	355	fatigue
O	355	356	.

O	357	367	Resistance
O	368	376	training
O	377	379	as
O	380	382	an
O	383	395	accompanying
O	396	405	treatment
O	406	408	to
O	409	421	chemotherapy
O	422	425	has
O	426	430	been
O	431	440	minimally
O	441	453	investigated
O	453	454	,
O	455	458	yet
O	459	464	might
O	465	475	counteract
O	476	482	muscle
O	483	494	degradation
O	495	498	and
O	499	511	inflammation
O	512	518	caused
O	519	521	by
O	522	526	many
O	527	544	chemotherapeutics
O	544	545	,
O	546	549	and
O	550	554	thus
O	555	564	forestall
O	565	567	or
O	568	574	reduce
O	575	582	fatigue
O	582	583	.

O	584	592	Previous
O	593	601	exercise
O	602	608	trials
O	609	615	mostly
O	616	624	compared
O	625	628	the
O	629	641	intervention
O	642	646	with
O	647	648	'
O	648	653	usual
O	654	658	care
O	658	659	'
O	659	660	.

O	661	670	Therefore
O	670	671	,
O	672	674	it
O	675	677	is
O	678	685	unclear
O	686	688	to
O	689	693	what
O	694	700	extent
O	701	704	the
O	705	713	observed
O	714	721	effects
O	722	724	on
O	725	732	fatigue
O	733	736	are
O	737	742	based
O	743	745	on
O	746	754	physical
O	755	766	adaptations
O	767	769	by
O	770	778	exercise
O	779	785	itself
O	785	786	,
O	787	789	or
O	790	796	rather
O	797	799	on
O	800	806	psycho
O	806	807	-
O	807	813	social
O	814	821	factors
O	822	828	linked
O	829	831	to
O	832	835	the
O	836	841	group
O	842	849	support
O	850	852	or
O	853	862	attention
O	863	865	by
O	866	869	the
O	870	877	trainer
O	877	878	.

O	879	882	The
O	883	888	BEATE
O	889	894	study
O	895	897	is
O	898	899	a
O	900	910	randomized
O	910	911	,
O	912	922	controlled
O	923	935	intervention
O	936	941	trial
O	942	951	comparing
O	952	953	a
O	954	956	12
O	956	957	-
O	957	961	week
O	962	972	supervised
O	973	984	progressive
O	985	995	resistance
O	996	1004	training
O	1005	1012	program
O	1013	1017	with
O	1018	1019	a
O	1020	1030	supervised
O	1031	1036	group
O	1036	1037	-
O	1037	1042	based
O	1043	1054	progressive
O	1055	1061	muscle
O	1062	1072	relaxation
O	1073	1081	training
O	1082	1084	in
B-total-participants	1085	1088	100
B-eligibility	1089	1097	patients
I-eligibility	1098	1102	with
I-eligibility	1103	1109	breast
I-eligibility	1110	1116	cancer
I-eligibility	1117	1122	under
I-eligibility	1123	1131	adjuvant
I-eligibility	1132	1144	chemotherapy
O	1144	1145	.

O	1146	1149	The
O	1150	1157	primary
O	1158	1166	endpoint
O	1167	1169	is
B-outcome-Measure	1170	1176	cancer
I-outcome-Measure	1176	1177	-
I-outcome-Measure	1177	1184	related
I-outcome-Measure	1185	1192	fatigue
O	1192	1193	;
O	1194	1203	secondary
O	1204	1213	endpoints
O	1214	1221	include
B-outcome-Measure	1222	1229	quality
I-outcome-Measure	1230	1232	of
I-outcome-Measure	1233	1237	life
O	1237	1238	,
B-outcome-Measure	1239	1249	depression
O	1249	1250	,
O	1251	1254	and
B-outcome-Measure	1255	1264	cognitive
I-outcome-Measure	1265	1273	capacity
O	1273	1274	.

O	1275	1277	In
O	1278	1286	addition
O	1286	1287	,
B-outcome-Measure	1288	1298	isokinetic
I-outcome-Measure	1299	1302	and
I-outcome-Measure	1303	1312	isometric
I-outcome-Measure	1313	1319	muscle
I-outcome-Measure	1320	1328	strength
O	1328	1329	,
B-outcome-Measure	1330	1347	cardiorespiratory
I-outcome-Measure	1348	1355	fitness
O	1355	1356	,
O	1357	1360	and
B-outcome-Measure	1361	1365	body
I-outcome-Measure	1366	1377	composition
O	1378	1381	are
O	1382	1390	measured
O	1390	1391	,
O	1392	1395	and
B-outcome-Measure	1396	1406	biomarkers
O	1406	1407	,
O	1408	1412	such
O	1413	1415	as
O	1416	1428	inflammatory
O	1429	1439	parameters
O	1439	1440	,
O	1441	1449	cortisol
O	1449	1450	,
O	1451	1454	and
O	1455	1464	oxidative
O	1465	1471	stress
O	1472	1475	are
O	1476	1484	analyzed
O	1485	1487	in
O	1488	1493	blood
O	1493	1494	,
O	1495	1501	saliva
O	1502	1505	and
O	1506	1511	urine
O	1511	1512	.

B-outcome-Measure	1513	1519	Safety
O	1520	1522	of
O	1523	1526	the
O	1527	1537	resistance
O	1538	1546	training
O	1547	1553	during
O	1554	1566	chemotherapy
O	1567	1569	is
O	1570	1579	monitored
O	1579	1580	.

O	1581	1590	Strengths
O	1591	1593	of
O	1594	1597	the
O	1598	1603	BEATE
O	1604	1609	study
O	1610	1617	include
O	1618	1621	the
O	1622	1635	investigation
O	1636	1638	of
O	1639	1650	progressive
O	1651	1661	resistance
O	1662	1670	training
O	1671	1679	parallel
O	1680	1684	with
O	1685	1697	chemotherapy
O	1697	1698	,
O	1699	1702	the
O	1703	1709	choice
O	1710	1712	of
O	1713	1714	a
O	1715	1722	control
O	1723	1728	group
O	1729	1733	that
O	1734	1741	enables
O	1742	1744	an
O	1745	1755	evaluation
O	1756	1758	of
O	1759	1762	the
O	1763	1776	physiological
O	1777	1784	effects
O	1785	1787	of
O	1788	1796	exercise
O	1797	1803	beyond
O	1804	1813	potential
O	1814	1820	psycho
O	1820	1821	-
O	1821	1827	social
O	1828	1835	effects
O	1835	1836	,
O	1837	1840	and
O	1841	1844	the
O	1845	1858	comprehensive
O	1859	1862	and
O	1863	1867	high
O	1867	1868	-
O	1868	1875	quality
O	1876	1886	assessment
O	1887	1889	of
O	1890	1903	physiological
O	1904	1911	factors
O	1912	1915	and
O	1916	1926	biomarkers
O	1927	1938	potentially
O	1939	1946	related
O	1947	1949	to
O	1950	1957	fatigue
O	1957	1958	.
